J Breast Cancer.  2016 Sep;19(3):336-338. 10.4048/jbc.2016.19.3.336.

Comments on the "Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer" and the "Commentary by Antonio Ieni and Giovanni Tuccari"

• Fargeas CA
• Corbeil D

• KMID: 2413961
• DOI: http://doi.org/10.4048/jbc.2016.19.3.336

Abstract

No abstract available.

MeSH Terms

Breast*

Reference

1. Kim SJ, Kim YS, Jang ED, Seo KJ, Kim JS. Prognostic impact and clinicopathological correlation of CD133 and ALDH1 expression in invasive breast cancer. J Breast Cancer. 2015; 18:347–355.

2. Ieni A, Tuccari G. Comments on the "Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer". J Breast Cancer. 2016; 19:96–98.

3. Hermansen SK, Christensen KG, Jensen SS, Kristensen BW. Inconsistent immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma. J Histochem Cytochem. 2011; 59:391–407.

4. Ieni A, Giuffrè G, Adamo V, Tuccari G. Prognostic impact of CD133 immunoexpression in node-negative invasive breast carcinomas. Anticancer Res. 2011; 31:1315–1320.

5. Han Z, Chen Z, Zheng R, Cheng Z, Gong X, Wang D. Clinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis. World J Surg Oncol. 2015; 13:56.

6. Zhao P, Lu Y, Jiang X, Li X. Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Cancer Sci. 2011; 102:1107–1111.

7. Mansour SF, Atwa MM. Clinicopathological significance of CD133 and ALDH1 cancer stem cell marker expression in invasive ductal breast carcinoma. Asian Pac J Cancer Prev. 2015; 16:7491–7496.

8. Aomatsu N, Yashiro M, Kashiwagi S, Takashima T, Ishikawa T, Ohsawa M, et al. CD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer. PLoS One. 2012; 7:e45865.

9. Bock C, Kuhn C, Ditsch N, Krebold R, Heublein S, Mayr D, et al. Strong correlation between N-cadherin and CD133 in breast cancer: role of both markers in metastatic events. J Cancer Res Clin Oncol. 2014; 140:1873–1881.

10. Lin CH, Liu CH, Wen CH, Ko PL, Chai CY. Differential CD133 expression distinguishes malignant from benign papillary lesions of the breast. Virchows Arch. 2015; 466:177–184.

11. Fargeas CA, Huttner WB, Corbeil D. Nomenclature of prominin-1 (CD133) splice variants: an update. Tissue Antigens. 2007; 69:602–606.

12. Corbeil D, Karbanová J, Fargeas CA, Jászai J. Prominin-1 (CD133): molecular and cellular features across species. Adv Exp Med Biol. 2013; 777:3–24.

13. Florek M, Haase M, Marzesco AM, Freund D, Ehninger G, Huttner WB, et al. Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res. 2005; 319:15–26.

14. Kemper K, Sprick MR, de Bree M, Scopelliti A, Vermeulen L, Hoek M, et al. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res. 2010; 70:719–729.

15. Karbanová J, Missol-Kolka E, Fonseca AV, Lorra C, Janich P, Hollerová H, et al. The stem cell marker CD133 (Prominin-1) is expressed in various human glandular epithelia. J Histochem Cytochem. 2008; 56:977–993.

16. Missol-Kolka E, Karbanová J, Janich P, Haase M, Fargeas CA, Huttner WB, et al. Prominin-1 (CD133) is not restricted to stem cells located in the basal compartment of murine and human prostate. Prostate. 2011; 71:254–267.

17. Immervoll H, Hoem D, Sakariassen PØ, Steffensen OJ, Molven A. Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer. 2008; 8:48.

18. Corbeil D. Prominin-1 (CD133): New Insights on Stem & Cancer Stem Cell Biology. . New York: Springer-Verlag;2013.

19. Corbeil D, Fargeas CA, Jászai J. CD133 might be a pan marker of epithelial cells with dedifferentiation capacity. Proc Natl Acad Sci U S A. 2014; 111:E1451–E1452.

20. Prat A, Perou CM. Mammary development meets cancer genomics. Nat Med. 2009; 15:842–844.

21. Weigmann A, Corbeil D, Hellwig A, Huttner WB. Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl Acad Sci U S A. 1997; 94:12425–12430.

22. Marzesco AM. Prominin-1-containing membrane vesicles: origins, formation, and utility. Adv Exp Med Biol. 2013; 777:41–54.

23. Bauer N, Wilsch-Bräuninger M, Karbanová J, Fonseca AV, Strauss D, Freund D, et al. Haematopoietic stem cell differentiation promotes the release of prominin-1/CD133-containing membrane vesicles: a role of the endocytic-exocytic pathway. EMBO Mol Med. 2011; 3:398–409.

24. Karbanová J, Laco J, Marzesco AM, Janich P, Voborníková M, Mokrý J, et al. Human prominin-1 (CD133) is detected in both neoplastic and non-neoplastic salivary gland diseases and released into saliva in a ubiquitinated form. PLoS One. 2014; 9:e98927.

25. O’Brien K, Rani S, Corcoran C, Wallace R, Hughes L, Friel AM, et al. Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells. Eur J Cancer. 2013; 49:1845–1859.

26. Latorre E, Carelli S, Raimondi I, D’Agostino V, Castiglioni I, Zucal C, et al. The ribonucleic complex HuR-MALAT1 represses CD133 expression and suppresses epithelial-mesenchymal transition in breast cancer. Cancer Res. 2016; 76:2626–2636.

27. Pötgens AJ, Schmitz U, Kaufmann P, Frank HG. Monoclonal antibody CD133-2 (AC141) against hematopoietic stem cell antigen CD133 shows crossreactivity with cytokeratin 18. J Histochem Cytochem. 2002; 50:1131–1134.

28. Anderson LH, Boulanger CA, Smith GH, Carmeliet P, Watson CJ. Stem cell marker prominin-1 regulates branching morphogenesis, but not regenerative capacity, in the mammary gland. Dev Dyn. 2011; 240:674–681.

29. Collina F, Di Bonito M, Li Bergolis V, De Laurentiis M, Vitagliano C, Cerrone M, et al. Prognostic value of cancer stem cells markers in triplenegative breast cancer. Biomed Res Int. 2015; 2015:158682.

30. Kapucuoğlu N, Bozkurt KK, BaBaşpınar Ş, Koçer M, Eroğlu HE, Akdeniz R, et al. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer. Pathol Res Pract. 2015; 211:740–747.